When you establish and nurture relationships with all your key partners in academia, government, industry and other patient advocacy organizations, you can form multi-stakeholder partnerships that maximize your ability to help accelerate therapy research and development.
When you connect with government officials at different agencies, you can help propel the development of an investigational therapy. For example, a patient group can encourage communication between the staff at the National Institutes of Health (NIH) and the scientists of their disease group. In addition, early interactions with Food and Drug Administration (FDA) staff can help inform patient perspectives during the regulatory process.
Many disease-specific nonprofit organizations focus on developing investigational therapies for rare diseases. You can connect with these groups to learn about best practices and new approaches or to support mutually beneficial projects. You can also connect with umbrella organizations to learn more about how to best organize your patient community and combine multi-stakeholder voices to advocate for medical research more effectively.